PCVX - Vaxcyte Inc logo

PCVX

Vaxcyte Inc

Rev —top 1%5Y
Hold

Vaxcyte develops vaccines to prevent and treat bacterial infections, focusing on conjugate and protein vaccines. Its lead candidate targets invasive pneumococcal disease, with additional candidates for diseases like Group A Streptococcus and dysentery.

⚕️ Healthcare NASDAQ Listed 2020 $ USD
$1,000 invested 5 years ago $2,237today

Score Overview

1 Year
Score
Net Growth-38.82%
Net TrendShrank
Net Income Consistency
Rev Growth
Rev TrendShrank
Revenue Consistency
5 Years
Score
Net Growth-8x
Net TrendNever
Net Income Consistency
Rev Growth
Rev TrendNever
Revenue Consistency
All Time
Score
Net Growth-9x
Net TrendNever
Net Income Consistency
Rev Growth
Rev TrendNever
Revenue Consistency

See the full market ranking →

Vaxcyte Inc fundamental performance

Across Vaxcyte Inc's full reported history, from 2020 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 89M to -$ 766M. Revenue increased in 0% of the years measured; net income in 0%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 59.65
1 Year2025-08-12
$ 30.0098.83%
5 Years2021-08-12
$ 26.66123.74%
All Time2020-06-12
$ 26.15128.11%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 1.06B$ 1.48B
2025$ 0.00-$ 766M$ 1.56B
2024$ 0.00-$ 463M$ 1.74B
2023$ 0.00-$ 402M$ 1.08B
2022$ 0.00-$ 223M$ 931M
2021$ 0.00-$ 100M$ 245M
IPO2020$ 0.00-$ 89M$ 386M

Explore beyond PCVX

You're looking at Vaxcyte Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies